JP2025508131A5 - - Google Patents
Info
- Publication number
- JP2025508131A5 JP2025508131A5 JP2024553807A JP2024553807A JP2025508131A5 JP 2025508131 A5 JP2025508131 A5 JP 2025508131A5 JP 2024553807 A JP2024553807 A JP 2024553807A JP 2024553807 A JP2024553807 A JP 2024553807A JP 2025508131 A5 JP2025508131 A5 JP 2025508131A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- antibody
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263318465P | 2022-03-10 | 2022-03-10 | |
| US63/318,465 | 2022-03-10 | ||
| PCT/US2023/064088 WO2023173055A2 (en) | 2022-03-10 | 2023-03-10 | Methods of treating cancer and other conditions with a mu opioid receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508131A JP2025508131A (ja) | 2025-03-21 |
| JP2025508131A5 true JP2025508131A5 (https=) | 2026-03-18 |
Family
ID=87936037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553807A Pending JP2025508131A (ja) | 2022-03-10 | 2023-03-10 | μオピオイド受容体アンタゴニストで癌および他の状態を処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186423A1 (https=) |
| EP (1) | EP4489866A4 (https=) |
| JP (1) | JP2025508131A (https=) |
| KR (1) | KR20250004644A (https=) |
| CN (1) | CN119584986A (https=) |
| AU (1) | AU2023231655A1 (https=) |
| CA (1) | CA3253916A1 (https=) |
| IL (1) | IL315501A (https=) |
| TW (1) | TW202400158A (https=) |
| WO (1) | WO2023173055A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025137697A1 (en) * | 2023-12-21 | 2025-06-26 | Glycyx Mor Inc. | Methods, systems, and compositions related to use of mu opioid receptor (mor) antagonists |
| CN121534059A (zh) * | 2024-08-09 | 2026-02-17 | 盐野义有限公司 | 一种治疗帕金森综合征或帕金森病的方法和药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| JP6686013B2 (ja) * | 2014-10-17 | 2020-04-22 | サリックス ファーマスーティカルズ，インコーポレーテッド | 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用 |
| EP3490542A4 (en) * | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| US12053523B2 (en) * | 2017-12-13 | 2024-08-06 | North Carolina State University | Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use |
| US11471459B2 (en) * | 2018-03-26 | 2022-10-18 | Fondazione Per L'istituto Oncologico Di Ricerca (Ior) | Compounds with enhanced anti-tumor effects |
| US20220125844A1 (en) * | 2020-10-23 | 2022-04-28 | The Johns Hopkins University | Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy |
-
2023
- 2023-03-09 TW TW112108783A patent/TW202400158A/zh unknown
- 2023-03-10 US US18/845,283 patent/US20250186423A1/en active Pending
- 2023-03-10 IL IL315501A patent/IL315501A/en unknown
- 2023-03-10 EP EP23767721.6A patent/EP4489866A4/en active Pending
- 2023-03-10 KR KR1020247033220A patent/KR20250004644A/ko active Pending
- 2023-03-10 JP JP2024553807A patent/JP2025508131A/ja active Pending
- 2023-03-10 CA CA3253916A patent/CA3253916A1/en active Pending
- 2023-03-10 WO PCT/US2023/064088 patent/WO2023173055A2/en not_active Ceased
- 2023-03-10 CN CN202380026567.3A patent/CN119584986A/zh active Pending
- 2023-03-10 AU AU2023231655A patent/AU2023231655A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508131A5 (https=) | ||
| Bachanova et al. | Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma | |
| Maitland et al. | First-in-human study of PF-06647020 (Cofetuzumab Pelidotin), an antibody–drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors | |
| Frentzas et al. | Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors | |
| Diab et al. | Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02) | |
| Balar et al. | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | |
| Besse et al. | Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer | |
| Doebele et al. | Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer | |
| DuBois et al. | Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study | |
| Qiao et al. | The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial | |
| Mita et al. | Phase 1 study of AMG 386, a selective angiopoietin 1/2–neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors | |
| Mezzano et al. | Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy | |
| JP2023098947A5 (https=) | ||
| Martin et al. | Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation | |
| Godwin et al. | Recent developments in the treatment of advanced bladder cancer | |
| Casak et al. | FDA's approval of the first biosimilar to bevacizumab | |
| de Klerk et al. | Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival | |
| McNerney et al. | HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL | |
| Ishiguro et al. | Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study | |
| Helissey et al. | Immune checkpoint inhibitors in advanced nonsmall cell lung cancer | |
| He et al. | Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment | |
| Charpidou et al. | Therapy-induced toxicity of the lungs: an overview | |
| Dorman et al. | Novel systemic treatment approaches for metastatic pancreatic cancer | |
| Lynch et al. | Efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma: primary analysis from a phase 2 study (CITADEL-203) | |
| Guo et al. | Traditional Chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors |